Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies
The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Tauopathies are clinicopathological entities with increased and pathological deposition in glia and/or neurons of hyperphosphorylated aggregates of the microtubule-binding protein tau. In secondary tauopathies, i.e. Alzheimer's disease (AD), tau deposition can be observed, but tau coexists with another protein (amyloid-β). In the last 20 years, little progress has been made in developing disease-modifying drugs for primary and secondary tauopathies and available symptomatic drugs have limited efficacy. AREAS COVERED: The present review summarized recent advances about the development and challenges in treatments for primary and secondary tauopathies, with a focus on passive tau-based immunotherapy. EXPERT OPINION: Several tau-targeted passive immunotherapeutics are in development for treating tauopathies. At present, 14 anti-tau antibodies have entered clinical trials, and 9 of them are still in clinical testing for progressive supranuclear palsy syndrome and AD (semorinemab, bepranemab, E2814, JNJ-63733657, Lu AF87908, APNmAb005, MK-2214, PNT00, and PRX005). However, none of these nine agents have reached Phase III. The most advanced anti-tau monoclonal antibody for treating AD is semorinemab, while bepranemab is the only anti-tau monoclonal antibody still in clinical testing for treating progressive supranuclear palsy syndrome. Further evidence on passive immunotherapeutics for treating primary and secondary tauopathies will come from ongoing Phase I/II trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“AADvac1 (24) is the first tau vaccine to enter clinical trials,469 aiming to inhibit tau aggregation, remove tau aggregates, prevent pathological spread, and slow disease progression.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [469]
In the citing paper
“Bepranemab (22, UCB0107), an antibody targeting the central region of tau, potentially inhibits tau aggregation and propagation.469”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [469]
Citations
Cites
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Classification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141 · cited 1×
“the behavioral variant of FTD (bvFTD) [24] and primary [25] progressive aphasia (PPA) [15].”
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492 · cited 1×
“These tau isoforms may have three or four repeat domains in the C-terminal part [35].”
BackgroundClinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Höglinger, G. U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K. A., Lang, A. E., Mollenhauer, B., Müller, U., Nilsson, C., Whitwell, J. L., et al. (2017) · Movement Disorders · doi:10.1002/mds.26987 · Cited by 2,359
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049 · cited 1×
“Given the importance of determining intracellular and extracellular forms of tau protein, increased CSF tau levels (mainly composed of tau fragments spanning 150–250 aa) in AD suggested that anti-tau antibodies targeting aa 150–250 may be beneficial in preventing extracellular tau spreading [75,76].”
Criteria for the diagnosis of corticobasal degeneration
Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0fd1 · Cited by 1,904 · cited 5×
“corticobasal syndrome (CBS) [26] and progressive supranuclear palsy syndrome (PSPS) [27], are also considered primary tauopathies linked to FTLD-Tau.”
InfluentialPrimary age-related tauopathy (PART): a common pathology associated with human aging
Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I., Arnold, S. E., Attems, J., Beach, T. G., Bigio, E. H., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1349-0 · Cited by 1,467 · cited 5×
“CONTACT Francesco Panza f_panza@hotmail.com Unit of Research Methodology and Data Sciences for Population Health, National Institute of Gastroenterology “Saverio de Bellis” Research Hospital, Castellana Grotte, Bari, Italy © 2023 Informa UK Limited, trading as Taylor & Francis Group Currently, we recognize three main…”
BackgroundInfluentialTau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · cited 2×
“One of the major drawbacks of anti-tau therapies is the uncertainty of whether the anti-tau agents catch misfolded tau en route from cell-tocell [59,70], or enters neurons or glia to destroy misfolded tau [71–73].”
BackgroundClinicopathological evaluation of chronic traumatic encephalopathy in players of American football
Mez, J., Daneshvar, D. H., Kiernan, P. T., Abdolmohammadi, B., Alvarez, V. E., Huber, B. R., Alosco, M. L., Solomon, T. M., Nowinski, C. J., McHale, L., et al. (2017) · JAMA · doi:10.1001/jama.2017.8334 · Cited by 1,098 · cited 3×
“In December 2019, another Phase I RCT (TauBasket, NCT03658135), investigating the efficacy of gosuranemab in four primary tauopathies (CBS, FTLD-tau, PPA, and CTE), was also discontinued on the basis of the negative findings of the Phase II PASSPORT study in PSPS [23].”
BackgroundMackenzie, I. R. A., Neumann, M., Bigio, E. H., Cairns, N. J., Alafuzoff, I., Kril, J., Kovacs, G. G., Ghetti, B., Halliday, G., Holm, I. E., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0612-2 · Cited by 1,012
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788 · cited 2×
“Oligonucleotide-based therapeutics with antisense and short interfering RNA may be a novel option for targeting tau mRNA and reducing the expression of total tau [40].”
BackgroundArendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609 · cited 1×
“However, in secondary tauopathies, the role of tau pathology may not necessarily be downstream to this other protein-associated pathology [4], so recommending to use the term mixed tauopathies.”
BackgroundNeve, R. L., Harris, P., Kosik, K. S., Kurnit, D. M., & Donlon, T. A. (1986) · Molecular Brain Research · doi:10.1016/0169-328x(86)90033-1 · Cited by 565
Wang, J.-Z., Xia, Y.-Y., Grundke-Iqbal, I., & Iqbal, K. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129031 · Cited by 532 · cited 1×
“In physiological conditions, this protein is unfolded and phosphorylated, while in primary/secondary tauopathies brains is hyperphosphorylated and aggregated with a β-pleated sheet conformation [31].”
Aging-related tau astrogliopathy (ARTAG): Harmonized evaluation strategy
Kovacs, G. G., Ferrer, I., Grinberg, L. T., Alafuzoff, I., Attems, J., Budka, H., Cairns, N. J., Crary, J. F., Duyckaerts, C., Ghetti, B., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1509-x · Cited by 532 · cited 4×
“Currently, we recognize three main age-related tauopathies: primary age-related tauopathy (PART) [12], aging-related tau astrogliopathy (ARTAG) [13], and argyrophilic grain disease (AGD) [14].”
InfluentialAsuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2361-07.2007 · Cited by 506
Invited review: Neuropathology of tauopathies: principles and practice
Kovacs, G. G. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12208 · Cited by 492 · cited 1×
“Currently, we recognize more than 26 different tauopathies [6], classified as primary and secondary/nonprimary tauopathies [7,8].”
BackgroundNeuropathological background of phenotypical variability in frontotemporal dementia
Josephs, K. A., Hodges, J. R., Snowden, J. S., Mackenzie, I. R., Neumann, M., Mann, D. M., & Dickson, D. W. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0839-6 · Cited by 459
Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
Barthélemy, N. R., Horie, K., Sato, C., & Bateman, R. J. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200861 · Cited by 437 · cited 1×
“namic and therapy mechanism interpretation, and RCT participants’ selection [83].”
BackgroundLoPresti, P., Szuchet, S., Papasozomenos, S. C., Zinkowski, R. P., & Binder, L. I. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.22.10369 · Cited by 388 · cited 1×
“In neurons, particularly within axons [29], and in oligodendrocytes and astrocytes [30], tau protein has several functions related in particular to axonal transport and the promotion of tubulin polymerization useful for the regulation of microtubule stability [28].”
BackgroundO’Brien, J. T., Holmes, C., Jones, M., Jones, R., Livingston, G., McKeith, I., Mittler, P., Passmore, P., Ritchie, C., Robinson, L., et al. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116680924 · Cited by 354
Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models
Chai, X., Wu, S., Murray, T. K., Kinley, R., Cella, C. V., Sims, H., Buckner, N., Hanmer, J., Davies, P., O'Neill, M. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229633 · Cited by 351 · cited 2×
“Given the importance of determining intracellular and extracellular forms of tau protein, increased CSF tau levels (mainly composed of tau fragments spanning 150–250 aa) in AD suggested that anti-tau antibodies targeting aa 150–250 may be beneficial in preventing extracellular tau spreading [75,76].”
Spillantini, M. G., Goedert, M., Crowther, R. A., Murrell, J. R., Farlow, M. R., & Ghetti, B. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.4113 · Cited by 334
PART is part of Alzheimer disease
Duyckaerts, C., Braak, H., Brion, J.-P., Buée, L., Del Tredici, K., Goedert, M., Halliday, G., Neumann, M., Spillantini, M. G., Tolnay, M., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1390-7 · Cited by 316 · cited 5×
“However, PART may represent a distinct entity, a prodromal phase of AD [15] or, alternatively, a putative cause of cognitive impairment in subjects with suspected nonAlzheimer’s disease pathophysiology (SNAP), with altered tau biomarkers and positive clinical AD criteria and without significant Aβ biomarkers [16].”
BackgroundInfluentialSuspected non-Alzheimer disease pathophysiology — concept and controversy
Jack, C. R., Knopman, D. S., Chételat, G., Dickson, D., Fagan, A. M., Frisoni, G. B., Jagust, W., Mormino, E. C., Petersen, R. C., Sperling, R. A., et al. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.251 · Cited by 306 · cited 1×
“However, PART may represent a distinct entity, a prodromal phase of AD [15] or, alternatively, a putative cause of cognitive impairment in subjects with suspected nonAlzheimer’s disease pathophysiology (SNAP), with altered tau biomarkers and positive clinical AD criteria and without significant Aβ biomarkers [16].”
BackgroundNovak, P., Schmidt, R., Kontsekova, E., Zilka, N., Kovacech, B., Skrabana, R., Vince-Kazmerova, Z., Katina, S., Fialova, L., Prcina, M., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30331-3 · Cited by 304 · cited 1×
“this vaccine and its follow-up open-label trial (NCT02031198) showed acceptable safety and effective immunogenicity, with stable cognitive measures and without attributable brain atrophy [55,56].”
Jeganathan, S., von Bergen, M., Mandelkow, E.-M., & Mandelkow, E. (2008) · Biochemistry · doi:10.1021/bi800783d · Cited by 286 · cited 1×
“In neurons, particularly within axons [29], and in oligodendrocytes and astrocytes [30], tau protein has several functions related in particular to axonal transport and the promotion of tubulin polymerization useful for the regulation of microtubule stability [28].”
BackgroundCastillo-Carranza, D. L., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., Gerson, J. E., Singh, G., Estes, D. M., Barrett, A. D. T., Dineley, K. T., Jackson, G. R., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3192-13.2014 · Cited by 278
Liquid–liquid phase separation of tau protein: The crucial role of electrostatic interactions
Boyko, S., Qi, X., Chen, T.-H., Surewicz, K., & Surewicz, W. K. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ac119.009198 · Cited by 271 · cited 1×
“The equilibrium between phosphorylation and dephosphorylation of protein tau controls the binding of tau protein to microtubules [32].”
Preliminary Findings: Behavioral Worsening on Donepezil in Patients With Frontotemporal Dementia
Mendez, M. F., Shapira, J. S., McMurtray, A., & Licht, E. (2007) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000231744.69631.33 · Cited by 267
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
Song, C., Shi, J., Zhang, P., Zhang, Y., Xu, J., Zhao, L., Zhang, R., Wang, H., & Chen, H. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00292-3 · Cited by 266
Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration
Gonzalez-Ortiz, F., Turton, M., Kac, P. R., Smirnov, D., Premi, E., Ghidoni, R., Benussi, L., Cantoni, V., Saraceno, C., Rivolta, J., et al. (2023) · Brain · doi:10.1093/brain/awac407 · Cited by 252 · cited 2×
“Attempts to develop accurate biomarkers and research networks for tauopathies are also underway [69].”
BackgroundKontsekova, E., Zilka, N., Kovacech, B., Novak, P., & Novak, M. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt278 · Cited by 248 · cited 1×
“sequence, coupled through an N-terminal cysteine to keyhole limpet hemocyanin, and administered with an Alhydrogel alum adjuvant [54].”
MethodBraak, H., & Braak, E. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90204-7 · Cited by 236 · cited 3×
“Finally, AGD has no clinical correlates [5] and presents silver-positive grainlike structures particularly in the medial temporal lobe [14].”
BackgroundHuman secreted tau increases amyloid-beta production
Bright, J., Hussain, S., Dang, V., Wright, S., Cooper, B., Byun, T., Ramos, C., Singh, A., Parry, G., Stagliano, N., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.09.007 · Cited by 230
Collin, L., Bohrmann, B., Göpfert, U., Oroszlan-Szovik, K., Ozmen, L., & Grüninger, F. (2014) · Brain · doi:10.1093/brain/awu213 · Cited by 208
Prion-like Properties of Tau Protein: The Importance of Extracellular Tau as a Therapeutic Target
Holmes, B. B., & Diamond, M. I. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.549295 · Cited by 202 · cited 2×
“In the brain, via conformational change, tau pathology can propagate in a prion-like way, while tau processing alterations may alter tau protein physiological functions [34].”
Teng, E., Manser, P. T., Pickthorn, K., Brunstein, F., Blendstrup, M., Sanabria Bohorquez, S., Wildsmith, K. R., Toth, B., Dolton, M., Ramakrishnan, V., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.1375 · Cited by 202
Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation
McEwan, W. A., Falcon, B., Vaysburd, M., Clift, D., Oblak, A. L., Ghetti, B., Goedert, M., & James, L. C. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607215114 · Cited by 201 · cited 1×
“In fact [74], anti-tau antibodies can cross the blood– brain barrier and enter neurons to target intracellular tau protein or bind extracellular tau so blocking the intercellular spread of tau pathology [59].”
BackgroundLananna, B. V., McKee, C. A., King, M. W., Del-Aguila, J. L., Dimitry, J. M., Farias, F. H. G., Nadarajah, C. J., Xiong, D. D., Guo, C., Cammack, A. J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax3519 · Cited by 201
Tauopathies as clinicopathological entities
Irwin, D. J. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.09.020 · Cited by 200
Congdon, E. E., Gu, J., Sait, H. B. R., & Sigurdsson, E. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.491001 · Cited by 195
CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease
Horie, K., Barthélemy, N. R., Sato, C., & Bateman, R. J. (2021) · Brain · doi:10.1093/brain/awaa373 · Cited by 180
Tauopathy-like Abnormalities and Neurologic Deficits in Mice Immunized With Neuronal Tau Protein
Rosenmann, H., Grigoriadis, N., Karussis, D., Boimel, M., Touloumi, O., Ovadia, H., & Abramsky, O. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1459 · Cited by 178 · cited 1×
“The first tau-based active immunization approach was to use full-length recombinant human tau to immunize C57BL/6 wild-type mice, unfortunately, this approach led to encephalomyelitis with neurological and behavioral deficits, inflammation, and axonal damage [52].”
MethodRandomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy
Litvan, I., Phipps, M., Pharr, V. L., Hallett, M., Grafman, J., & Salazar, A. (2001) · Neurology · doi:10.1212/wnl.57.3.467 · Cited by 163
Dam, T., Boxer, A. L., Golbe, L. I., Höglinger, G. U., Morris, H. R., Litvan, I., Lang, A. E., Corvol, J., Aiba, I., Grundman, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01455-x · Cited by 160 · cited 2×
“In PSPS patients treated with gosuranemab, CSF levels of unbound N-terminal tau decreased by 98% and increased by 11% in placebotreated patients, while AEs and deaths were similar between these two groups [67].”
BackgroundResultHöglinger, G. U., Litvan, I., Mendonca, N., Wang, D., Zheng, H., Rendenbach-Mueller, B., Lon, H.-K., Jin, Z., Fisseha, N., Budur, K., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30489-0 · Cited by 145 · cited 2×
“Trial findings confirmed target engagement by a decrease in CSF levels of free tau and higher plasma total tau in treated patients, but tilavonemab showed no efficacy, although no treatment-related AEs were reported [68].”
Self-citationTherapy and clinical trials in frontotemporal dementia: past, present, and future
Tsai, R. M., & Boxer, A. L. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13640 · Cited by 143 · cited 1×
“In fact, currently, for primary tauopathies, we have no US FDA-approved disease-modifying agents, except riluzole for FTD-amyotrophic lateral sclerosis (ALS) [44], focusing treatment on the neuropsychiatric symptom management.”
BackgroundBoxer, A. L., Qureshi, I., Ahlijanian, M., Grundman, M., Golbe, L. I., Litvan, I., Honig, L. S., Tuite, P., McFarland, N. R., O'Suilleabhain, P., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30139-5 · Cited by 139 · cited 1×
“85, statistically significant brain atrophy was observed in treated patients compared with those on placebo [66].”
Roberts, M., Sevastou, I., Imaizumi, Y., Mistry, K., Talma, S., Dey, M., Gartlon, J., Ochiai, H., Zhou, Z., Akasofu, S., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-0884-2 · Cited by 135 · cited 1×
“E2814 recognized pathological tau structures in postmortem brain, including NFTs from AD and PSPS [64].”
BackgroundAstrogliopathy predominates the earliest stage of corticobasal degeneration pathology
Ling, H., Kovacs, G. G., Vonsattel, J. P. G., Davey, K., Mok, K. Y., Hardy, J., Morris, H. R., Warner, T. T., Holton, J. L., & Revesz, T. (2016) · Brain · doi:10.1093/brain/aww256 · Cited by 133
Kovacs, G. G., Robinson, J. L., Xie, S. X., Lee, E. B., Grossman, M., Wolk, D. A., Irwin, D. J., Weintraub, D., Kim, C. F., Schuck, T., et al. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlx007 · Cited by 132 · cited 1×
“This neuropathological pattern of tau astrogliopathy was found in subpial, subependymal, or perivascular spaces, and primarily in the medial temporal lobe/amygdala [17].”
BackgroundLee, S.-H., Le Pichon, C. E., Adolfsson, O., Gafner, V., Pihlgren, M., Lin, H., Solanoy, H., Brendza, R., Ngu, H., Foreman, O., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.099 · Cited by 125
Development of disease-modifying drugs for frontotemporal dementia spectrum disorders
Panza, F., Lozupone, M., Seripa, D., Daniele, A., Watling, M., Giannelli, G., & Imbimbo, B. P. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0330-x · Cited by 122 · cited 4×
“In December 2019, another Phase I RCT (TauBasket, NCT03658135), investigating the efficacy of gosuranemab in four primary tauopathies (CBS, FTLD-tau, PPA, and CTE), was also discontinued on the basis of the negative findings of the Phase II PASSPORT study in PSPS [23].”
BackgroundInfluentialSelf-citationInternational FTD-Genomics Consortium (IFGC), Yokoyama, J. S., Karch, C. M., Fan, C. C., Bonham, L. W., Kouri, N., Ross, O. A., Rademakers, R., Kim, J., Wang, Y., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1693-y · Cited by 112 · cited 9×
“The development of potentially diseasemodifying treatment for FTLD-Tau (primary tauopathies) has been guided by recent advancements in the understanding of the neuropathology and pathophysiology of these diseases [8,23].”
BackgroundInfluentialResurrecting the Mysteries of Big Tau
Fischer, I., & Baas, P. W. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.04.007 · Cited by 112 · cited 1×
“For this reason, this isoform is mainly expressed in peripheral nervous system rather than in tauopathies [36].”
BackgroundAyalon, G., Lee, S.-H., Adolfsson, O., Foo-Atkins, C., Atwal, J. K., Blendstrup, M., Booler, H., Bravo, J., Brendza, R., Brunstein, F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb2639 · Cited by 110 · cited 2×
“In cell culture and a transgenic mouse model of tauopathy, a murine version of this monoclonal antibody reduced tau-related toxicity and tau accumulation, respectively [60].”
BackgroundTau-Based Therapeutics for Alzheimer’s Disease: Active and Passive Immunotherapy
Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B. P., Lozupone, M., Santamato, A., Tortelli, R., Galizia, I., Prete, C., Daniele, A., et al. (2016) · Immunotherapy · doi:10.2217/imt-2016-0019 · Cited by 105 · cited 1×
“The most advanced of these tau-based approaches is passive immunotherapy [23,37,38].”
BackgroundSelf-citationBussière, T., Hof, P. R., Vanbesien-Mailliot, C., Brown, C., Caillet‐Boudin, M., Perl, D. P., Buée, L., & Delacourte, A. (1999) · Acta Neuropathologica · doi:10.1007/s004010050978 · Cited by 102 · cited 1×
“body disorders, Down’s syndrome [11], and Niemann-Pick disease-type C [11] are other secondary/mixed tauopathies.”
BackgroundSpillantini, M. G., Tolnay, M., Love, S., & Goedert, M. (1999) · Acta Neuropathologica · doi:10.1007/s004010051034 · Cited by 86
Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau
Josephs, K. A. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.04.016 · Cited by 80 · cited 1×
“Finally, AGD has no clinical correlates [5] and presents silver-positive grainlike structures particularly in the medial temporal lobe [14].”
BackgroundCurrent directions in tau research: Highlights from Tau 2020
Sexton, C., Snyder, H., Beher, D., Boxer, A. L., Brannelly, P., Brion, J., Buée, L., Cacace, A. M., Chételat, G., Citron, M., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12452 · Cited by 79 · cited 1×
“Currently, we recognize more than 26 different tauopathies [6], classified as primary and secondary/nonprimary tauopathies [7,8].”
BackgroundCholinesterase inhibitors for rarer dementias associated with neurological conditions
Li, Y., Hai, S., Zhou, Y., & Dong, B. R. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009444.pub3 · Cited by 78
Frisardi, V., Solfrizzi, V., Capurso, C., Kehoe, P. G., Imbimbo, B. P., Santamato, A., Dellegrazie, F., Seripa, D., Pilotto, A., Capurso, A., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1340 · Cited by 64
Self-citationN-terminal Truncation of Microtubule Associated Protein Tau Dysregulates its Cellular Localization
Paholikova, K., Salingova, B., Opattova, A., Skrabana, R., Majerova, P., Zilka, N., Kovacech, B., Zilkova, M., Barath, P., & Novak, M. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140996 · Cited by 50 · cited 1×
“The first tau-based vaccine to enter clinical trials was AADvac1, designed to target misfolded tau protein in AD, an approach based on tau cleavage generating N-terminally truncated fragments [53].”
Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies
d’Abramo, C., Acker, C. M., Jimenez, H., & Davies, P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0135774 · Cited by 48 · cited 1×
“Passive immunotherapeutics with anti-tau monoclonal antibodies induced modest and quite variable reduction in tau pathology especially in those targeting phospho-tau epitope [76,77].”
BackgroundLiepelt, I., Gaenslen, A., Godau, J., Di Santo, A., Schweitzer, K. J., Gasser, T., & Berg, D. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2009.04.1231 · Cited by 47
Emerging Diagnostic and Therapeutic Strategies for Tauopathies
Coughlin, D., & Irwin, D. J. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0779-1 · Cited by 38 · cited 1×
“At present, the gold diagnostic standard for tauopathies remains the neuropathological examination at autopsy, and we cannot identify tauopathies antemortem without a clinical test specifically designed for this aim [19].”
BackgroundANTISENSE OLIGONUCLEOTIDES: A NEW TOOL IN NEUROSCIENCE
Pilowsky, P. M., Suzuki, S., & Minson, J. B. (1994) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1994.tb02655.x · Cited by 36 · cited 2×
“ASOs were the first compounds to target tau at the genetic level, suggesting that a relevant reduction of CSF tau protein may be welltolerated and safe [39,80].”
BackgroundMemantine for the treatment of frontotemporal dementia: a meta-analysis
Kishi, T., Matsunaga, S., & Iwata, N. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s94430 · Cited by 35
Lozupone, M., Imbimbo, B. P., Balducci, C., Vecchio, F. L., Bisceglia, P., Latino, R. R., Leone, M. A., Dibello, V., Solfrizzi, V., Greco, A., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12728 · Cited by 30 · cited 2×
“In fact, APOE genotype may provide guidance in drug-related risk stratification given that the presence of APOE e4 allele in patients treated with aducanumab is strongly associated with amyloid-related imaging abnormalities and exhibits a gene-dose effect [79].”
BackgroundSelf-citationTau-targeting antibody therapies: too late, wrong epitope or wrong target?
Jabbari, E., & Duff, K. (2021) · Nature Medicine · doi:10.1038/s41591-021-01465-9 · Cited by 29 · cited 1×
“Reasons for futility in RCTs include difficulties in earlier diagnosis of PSPS, especially preclinical stages, non-effective epitopes, and extracellular targeting [81].”
BackgroundCyclic dipeptide‐based small molecules modulate zinc‐mediated liquid–liquid phase separation of tau
Ramesh, M., Balachandra, C., Baruah, P., & Govindaraju, T. (2022) · Journal of Peptide Science · doi:10.1002/psc.3465 · Cited by 28
Moore, E. E., Gifford, K. A., Khan, O. A., Liu, D., Pechman, K. R., Acosta, L. M. Y., Bell, S. P., Turchan, M., Landman, B. A., Blennow, K., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12087 · Cited by 26 · cited 1×
“of MAPT mutations who are relatively young and have established tau pathology [82], although carriers of a MAPT muta-”
BackgroundShoeibi, A., Olfati, N., & Litvan, I. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1460356 · Cited by 23 · cited 1×
“Given the shared NFT pathology among primary and secondary tauopathies, positive findings from this RCT might suggest the use of AADvac1 for primary tauopathies such as PSPS [57].”
The challenges of anti-tau therapeutics in Alzheimer disease
Panza, F., & Lozupone, M. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00702-0 · Cited by 23 · cited 10×
“Furthermore, the drug did not reduce markers linked to neuronal degeneration and inflammation in CSF [i.e. soluble triggering receptor expressed on myeloid cells 2 (sTREM2), neurogranin, neurofilament light chain, interleukin-6, and S100B] [38].”
BackgroundMethodInfluentialSelf-citationLozupone, M., Dibello, V., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Stallone, R., Altamura, M., Bellomo, A., et al. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2200245 · Cited by 21 · cited 6×
“clinical trial (RCT) of BIIB080 in mild AD (NCT03186989) [39].”
BackgroundInfluentialSelf-citationDisease-modifying therapies for tauopathies: agents in the pipeline
Panza, F., Imbimbo, B. P., Lozupone, M., Greco, A., Seripa, D., Logroscino, G., Daniele, A., & Colosimo, C. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1606715 · Cited by 20 · cited 4×
“response, with reduced tau protein, and improvement of the cognitive and behavioral phenotypes [8].”
BackgroundInfluentialSelf-citationAnti-tau vaccine in Alzheimer's disease: a tentative step
Panza, F., & Logroscino, G. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30340-4 · Cited by 12 · cited 1×
“this vaccine and its follow-up open-label trial (NCT02031198) showed acceptable safety and effective immunogenicity, with stable cognitive measures and without attributable brain atrophy [55,56].”
Self-citation
Research works printed but not linked: 1
- Eli Lilly press release. https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-significantly-slowed-cognitive-and-functional
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Gaikwad, S., Senapati, S., Haque, M. A., & Kayed, R. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13490 · Cited by 117
Shen, X., Li, H., Zhang, B., Li, Y., & Zhu, Z. (2025) · Cells · doi:10.3390/cells14191506 · Cited by 35
“LuAF-87908 is a humanised IgG1 antibody directed against pTau, while MK-2214 specifically targets the Ser413 phosphorylation site, a residue implicated in tau pathology [153,154].”
Bispecific brain-penetrant antibodies for treatment of Alzheimer’s disease
Sehlin, D., Hultqvist, G., Michno, W., Aguilar, X., Dahlén, A. D., Cerilli, E., Bucher, N. M., van den Broek, S. L., & Syvänen, S. (2025) · The journal of prevention of Alzheimer's disease · doi:10.1016/j.tjpad.2025.100214 · Cited by 30
Rawal, S., Wildsmith, K. R., Aluri, J., Yagi, T., Chang, M., Niu, H., Zhou, J., Horie, K., Takahashi, E., Boyd, P., et al. (2025) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000680 · Cited by 26
Metadata
- Authors
- Panza, F., Dibello, V., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Stallone, R., Cirillo, N., Damiani, C., Altamura, M., Bellomo, A., Daniele, A., Solfrizzi, V., & Lozupone, M.
- Affiliations
- Gastroenterology Hospital "Saverio de Bellis" (IT)
- Academic Center for Dentistry Amsterdam (NL)
- University of Bari Aldo Moro (IT)
- University of Foggia (IT)
- Università Cattolica del Sacro Cuore (IT)
- Corresponding author
- Panza, Francesco
- ORCID
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2023-07-03
- Volume
- 32
- Issue
- 7
- Pages
- 625-634
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W4383186645
- Cited by
- 22
- References
- 82
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 5 · 2023: 1
- FWCI
- 0.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- VU Research Portal (submittedVersion)
- Funders
- Ministry of Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- tauopathy, passive immunotherapy, tau aggregation, Alzheimer's disease, progressive supranuclear palsy, disease-modifying drugs, clinical trials, amyloid-beta
- MeSH terms
- Alzheimer Disease, Antibodies, Monoclonal, Humans, Immunotherapy, Supranuclear Palsy, Progressive, tau Proteins, Tauopathies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.